Don't know why you'd think that. This is a pretty quiet thread. Several analysts have ~$13 targets for MACK, but they need to get a little further down the road to reach that.
I can't tell from your post if you're familiar with fast Track, but it doesn't speed up the process all that much. Any little bit is good for the patients, though.
I've owned it for some time and think that it's pretty fairly valued at the moment. Not really expecting it to break $10 in the immediate future, or to be able to hold it if it does. That said, it's had good bid support lately and may surprise me. I would be in favor of that!